top of page
LEADING THE EFFORT IN CLINICAL TRANSLATION
A fundamental shift has taken place in our understanding of TGF-β biology which has significant implications for how we treat TGF-β-driven diseases.
Venn Therapeutics is a precision medicine company. We are developing a pipeline of novel, best-in-class agents that precisely target key mechanisms of fibrosis and NASH.
C6D4 called VTX-001. Cryo-EM Reveals Integrin-Mediated TGF-b Activation without Release from Latent TGF-b, Nishimura et.al
bottom of page